Bone Therapeutics (0R55) Stock Statistics & Valuation Metrics

Bone Therapeutics has a market cap or net worth of €1.57M. The enterprise value is ―.

Bone Therapeutics has 652,862,300 shares outstanding. The number of shares has decreased by -2.65% in one year.

Bone Therapeutics’s return on equity (ROE) is -10.70 and return on invested capital (ROIC) is -71.55%.

The current PE Ratio of Bone Therapeutics is <0.1. Bone Therapeutics’s PEG ratio is ―.

In the last 12 months, Bone Therapeutics had revenue of 0.00 and earned 20.93M in profits. Earnings per share was 0.03.

In the last 12 months, operating cash flow was -1.18M and capital expenditures 1.18M, giving a free cash flow of 0.00 billion.

Bone Therapeutics pays an annual dividend of €0.285, resulting in a dividend yield of ―

Bone Therapeutics upcoming earnings date is Apr 23, 2026, Before Open (Confirmed).

Bone Therapeutics as a current ratio of 0.55, with Debt / Equity ratio of -194.58%

In the past 12 months, Bone Therapeutics has paid 0.00 in taxes.

Bone Therapeutics EV to EBITDA ratio is -3.96, with an EV/FCF ratio of 0.00.

Bone Therapeutics has €69.00K in cash and marketable securities with €26.79M in debt, giving a net cash position of -€3.74M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Bone Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―